Stereotactic body radiotherapy and hormone treatment resulted in 40.1% 12-month progression-free survival in a recent study. Administration of radiotherapy in conjunction with hormone treatment has ...

SBRT showed improved LPFS over RFA in treating single recurrent small HCC, especially for tumors ≤2 cm. Both SBRT and RFA demonstrated similar PFS, OS, and safety profiles, with mild to moderate side ...

The use of magnetic resonance–guided daily adaptive stereotactic body radiotherapy (SBRT) for patients with prostate cancer reduces the risk of acute urinary side effects of grade 2 or higher by 44% ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Shekinah Elmore, ...

Magnetic resonance (MR)‐guided adaptive stereotactic body radiotherapy (SBRT) for prostate cancer was associated with significantly lower rates of acute genitourinary and gastrointestinal toxicities ...

Stereotactic body radiation therapy (SBRT) has emerged as a cornerstone in the treatment of colorectal liver metastases, now featured in national and international guidelines from organizations such ...

Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...

Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Comparative data on sequential transarterial chemoembolization (TACE) after stereotactic body radiation therapy (SBRT) in recurrent hepatocellular carcinoma (HCC) remain limited. This study aimed to ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...